ICON Public Limited Company ICLR

NASDAQ | Biotech | Clinical research and drug development

General analysis — not personal advice.

Signal
NEUTRAL
Market sentiment
Neutral
Risk assessment
High

While the investigation conclusion reduces one overhang and the market has repriced accordingly, confirmed material weaknesses, pending restatements, and Nasdaq compliance/reporting risk warrant a reassessment before moving to a clear add/reduce stance.

Follow ICON Public free Follow free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Updated: 7 Jun 2026
Exchange
NASDAQ
Type
Biotech
Sector
Clinical research and drug development

Market sentiment

Sentiment has improved from a crisis/non-reliance narrative to cautious relief after the investigation conclusion and new guidance, but remains mixed due to restatement needs, control weaknesses, and reporting/compliance uncertainty.

Why this signal

While the investigation conclusion reduces one overhang and the market has repriced accordingly, confirmed material weaknesses, pending restatements, and Nasdaq compliance/reporting risk warrant a reassessment before moving to a clear add/reduce stance. Key watch items are the restatement timeline, remediation progress, and delivery versus 2026 guidance.

  • Wait/review: hold only if you can tolerate elevated governance and reporting risk; consider delaying new buys until restatement and internal-control remediation visibility improves.

We're already tracking ICON Public Limited Company — here are the latest events we've registered

Recent News

  • On July 29, 2026, ICON reported its second-quarter 2026 financial results, generating revenue of $2.06 billion and reaching a closing backlog of $23.4 billion. The company reaffirmed its full-year 2026 financial guidance, targeting revenue between $7.85 billion and $8.15 billion. Additionally, in August 2026, ICON announced the pricing of a $2.15 billion senior notes offering.

Catalysts

Restatements for 2023–2024

What Firelda Watch includes for ICON Public Limited Company

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of ICON Public Limited Company will be delivered in the same format.
Follow ICON Public free Follow free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

ICON Public Limited Company ICLR
ICON Public — this picture changes. Follow free
Follow ICON Public free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.